Clinical application for pathophysiological analysis, diagnosis and treatment of lung diseases by genes and their products expressed in alveolar type II cells.
Clinical application for pathophysiological analysis, diagnosis and treatment of lung diseases by genes and their products expressed in alveolar type II cells.
批准号:
12557057
负责人:
KUROKI Yoshio
金额:
$8.51万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study was to pursue clinical application for pathophysiological analysis, diagnosis and treatment of lung diseases by genes and their products expressed in alveolar type II cells. We have identified the antigen to autoantibody existing in sera from patients with idiopathic interstitial pneumonia (IIP), established clinical significance of serum SP-A and SP-D as disease markers and applied lung collectins and pattern recognition receptors for treatment of respiratory infections.(1) When A549 cell line was examined for immunoreactivity with sera from patients with IIP, approximately 50 % of patient sera reacted positively with A549 cells. Confocal microscopy revealed that the antigen recognized by patient sera localized in the cyoplasm of the cells. Patient IgG immunoprecipitaed 120 kDa protein. Proteome analysis of the 120 kDa protein identified the antigen as alanyl tRNA synthetase. We have cloned DNA for alanyl tRNA synthetase. When we analyzed immunocytochemically … More CHO cells which had been shown to be negative staining for patient IgG and were transfected with CDNA for this enzyme, patient IgG recognized the antigen in CHO cells that colocalized with GFP-labeled alanyl tRNA synthetase. In addition, sera from IIP patients significantly inhibited the enzyme activities of alanyl tRNA synthetase. These results clearly demonstrate that there exists antoantibody to alanyl tRNA synthetase in sera from IIP patients.(2) Serum SP-A and SP-D increased in patients with radiation pneumonitis. SP-A and SP-D appeared to respond to the small lung damages which was able to detect by CT but not by chest Xp, demonstrating the serological usefulness of SP-A and SP-D as disease markers. In addition, we have establised the detection system of micrometastasis in peripheral blood in patients with lung adenocarcinoma using RT-PCR for SP-A, SP-C and CC10.(3) We have analyzed the structure-function relationship of Toll-like receptor 2 that has been shown to interact with SP-A and SP-D. and identified the TLR2 region Ser40-Ile64 as the functional region in recognition and signal transduction of Staphylococcal peptidoglycan. Less
期刊论文(138)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Mitsuzawa H.: "Extracellular Toll-like receptor 2 region containing Ser40-Ile64 but not Cys30-Ser39 is critical for the recognition of Staphylococcus aur bus peptidoglycan"J. Biol. Chem.. 276. 6830-6837 (2002)
Mitsuzawa H.:“含有 Ser40-Ile64 但不含 Cys30-Ser39 的细胞外 Toll 样受体 2 区域对于识别金色葡萄球菌肽聚糖至关重要”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Cheng G: "Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma"Eur Respir J. 16. 831-835 (2000)
Cheng G:“支气管哮喘患者支气管肺泡灌洗液中表面活性蛋白 A 和 D 水平升高”Eur Respir J. 16. 831-835 (2000)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Takahashi H: "Serum levels of surfactant proteins A and D are useful markers for interstitial lung disease in patients with progressive systemic sclerosis."Am J Respir Crit Care Med. 162. 258-263 (2000)
Takahashi H:“表面活性蛋白 A 和 D 的血清水平是进行性系统性硬化症患者间质性肺疾病的有用标志物。”Am J Respir Crit Care Med。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
高橋亨: "GM-CSFノックアウトマウス"分子呼吸器病. (印刷中). (2001)
Toru Takahashi:“GM-CSF 敲除小鼠”分子呼吸道疾病(印刷中)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Takahashi H: "Serum levels of surfactant protein A and D are useful markers for interstitial lung disease in natients with progressive systemic sclerosis"Am J Respir Crit care Med. 62. 258-263 (2000)
Takahashi H:“表面活性蛋白 A 和 D 的血清水平是进行性系统性硬化症患者间质性肺疾病的有用标志物”Am J Respir Crit care Med。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 55 条
Mechanisms of host defense against pulmonaryinfection, inflammation and injury by surfactant proteins and studies on clinical applications
-
批准号:20390232
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.9万
-
财政年份:2008
-
负责人:KUROKI Yoshio
-
依托单位:
Host defense system in the lung using pulmonary surfactant proteins and Toll-like reosptors
-
批准号:18390241
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.12万
-
财政年份:2006
-
负责人:KUROKI Yoshio
-
依托单位:
Mechanisms of innate immune surveillance by pulmonary surfactant proteins and their clinical application to respiratory infection.
-
批准号:16390235
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.09万
-
财政年份:2004
-
负责人:KUROKI Yoshio
-
依托单位:
Molecular mechanisms of innate immune host defense mediated by lung-surfactant proteins A and D
-
批准号:12470136
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.22万
-
财政年份:2000
-
负责人:KUROKI Yoshio
-
依托单位:
Host defense mechanism by pulmonary surfactant proteins A and D thiir clinical application
-
批准号:10557058
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.62万
-
财政年份:1998
-
负责人:KUROKI Yoshio
-
依托单位:
Host defense mechanism and modulation of lipid metabolism by pulmonary surfactant proteins
-
批准号:09670159
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:1997
-
负责人:KUROKI Yoshio
-
依托单位:
Molecular mechanism of lung discases by analysis of surfactant protein A and its receptor.
-
批准号:07457147
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$0.83万
-
财政年份:1995
-
负责人:KUROKI Yoshio
-
依托单位:
Regulatory roles of pulmonary surfactant apoprotein and its receptor in metabolism of lung diseases.
-
批准号:03670406
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.28万
-
财政年份:1991
-
负责人:KUROKI Yoshio
-
依托单位:
海外基金